The Bank of Japan is likely to hold its key interest rate through June, showed a Reuters survey of economists, with a ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Belo, a member of PRWeek’s 2024 Health Influencer list, joined Takeda in 2021 as VP and global head of external communications. The company promoted him to SVP and head of global corporate brand and ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with ...

Michael Laroche; Chief Accounting Officer, Vice President, Controller; RPM International Inc Russell Gordon; Chief Financial Officer, Vice President; RPM International Inc Good day and welcome to ...

Indie game developer and publisher Rogueside revealed their latest game today, as Devil Jam will be coming to Steam sometime this Summer. The game will have you playing a rocker who just found ...

In Q3, we delivered our highest cannabis gross margins in almost two years, and as of today our net debt is now less than 1x EBITDA on a trailing twelve-month basis. We will not seek sales growth ...

"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform," said Martin Welschof, Chief Executive Officer of BioInvent.

Adjusted EPS for fiscal Q3 2025 was $0.35, missing estimates for $0.50. Revenue of $1.48 billion was short of estimates by $34 million. Net income of $52.0 million was down 15% year over year.

Those with myalgia exhibited a higher frequency of behaviors such as teeth clenching and grinding during sleep (Q1), teeth grinding and clenching during wakefulness and holding teeth together (Q3, Q4, ...